Format

Send to

Choose Destination
Biomed Pharmacother. 2017 Mar;87:755-758. doi: 10.1016/j.biopha.2017.01.118. Epub 2017 Jan 30.

Paclitaxel-releasing mesenchymal stromal cells inhibit in vitro proliferation of human mesothelioma cells.

Author information

1
Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy. Electronic address: francesco.petrella@ieo.it.
2
CRC-StaMeTec, Department of Biomedical, Surgical and Dental Sciences, University of Milan, Milan, Italy; I.R.C.C.S. Galeazzi Orthopedic Institute, Milan, Italy.
3
Hospital Pharmacy, European Institute of Oncology, Milan, Italy.
4
Department of Cerebrovascular Diseases, Fondazione IRCCS Neurological Institute Carlo Besta, Milan, Italy.
5
Oncology Research Center of Mercogliano (CROM), Istituto Nazionale per Lo Studio E La Cura Dei Tumori "Fondazione Giovanni Pascale", IRCCS, Naples, Italy.
6
Department of Thoracic Surgery, European Institute of Oncology, Milan, Italy; Department of Oncology and Hemato-oncology, University of Milan, Milan, Italy.

Abstract

INTRODUCTION:

Malignant pleural mesothelioma (MPM) is a rare fatal asbestos-related malignancy originating in the mesothelial cells of the pleura. A platinum-based doublet containing a third-generation antifolate is the front-line standard of care whilst there are no approved second-line treatments for MPM which remains a disease setting to test the efficacy of new therapeutic agents.

METHODS:

Bone marrow mesenchymal stromal cells (BM-MSCs) were loaded with pemetrexed (PMX) and paclitaxel (PTX) according to a standardized procedure. Drug release by both PMX- and PTX-primed BM-MSCs (BM-MSCs/PMX and BM-MSCs/PTX) was tested on the in vitro proliferation of a panel of tumor cell lines including NCI-H28 mesothelioma.

RESULTS:

The in vitro anticancer activity of pure PTX was significantly higher than that of PMX against all the cell lines tested (14.7 times higher than that of PMX against NCI-H28). Whereas BM-MSCs did not take up and release PMX in amounts effective on mesothelioma, PTX-loaded BM-MSCs dramatically inhibited mesothelioma proliferation.

CONCLUSIONS:

PTX-primed mesenchymal stromal cells successfully inhibit the in vitro proliferation of human mesothelioma cells. Further studies and in vivo testing are required to confirm our preliminary in vitro results as a potential new mesothelioma therapy based on cell drug delivery.

KEYWORDS:

Cell drug delivery; Mesenchymal stromal cells; Mesothelioma; Paclitaxel; Pemetrexed

PMID:
28153512
DOI:
10.1016/j.biopha.2017.01.118
[Indexed for MEDLINE]

Supplemental Content

Full text links

Icon for Elsevier Science
Loading ...
Support Center